Sequencing, the process of reading the precise order of letters in DNA, has become one of the most consequential technologies in modern science and medicine. It underpins how doctors diagnose rare diseases, how public health agencies track viral outbreaks, how researchers breed hardier crops, and how scientists reconstruct human history. What once cost roughly $300 million to sequence a single human genome now costs under $1,500, and that plummeting price has opened doors across nearly every field that touches biology.
Diagnosing Diseases That Otherwise Take Years to Identify
For families dealing with unexplained symptoms, sequencing can compress what is often a years-long journey through specialist after specialist into a matter of days. A study from UC Santa Cruz found that newer long-read sequencing technology delivered conclusive diagnoses for about one in four patients in a cohort of 42 people with rare diseases, providing information that older methods had missed entirely. The technology works as a single diagnostic test, eliminating the need for multiple rounds of clinical visits and separate genetic assays.
In pediatric settings, where early diagnosis can change the course of treatment, the lab processing time for a full genome sequence is now around four days. For critically ill children, a clinician report can follow in as few as five days total. For outpatients, the wait stretches longer (averaging about 74 days), largely because of scheduling and clinical review rather than technical limitations. The speed matters because for many rare genetic conditions, earlier intervention leads to better outcomes.
Guiding Cancer Treatment
In oncology, sequencing a tumor’s DNA reveals the specific mutations driving a patient’s cancer, which helps oncologists choose therapies that target those mutations rather than relying solely on broad-spectrum chemotherapy. This approach, often called precision medicine, matches patients with drugs designed to exploit the weaknesses in their particular cancer cells. It can also identify whether a patient qualifies for a clinical trial testing a new targeted therapy.
The reality, though, is still catching up to the promise. Currently about 8% of patients with advanced solid tumors receive a therapy directly guided by comprehensive genomic profiling, though that proportion has been improving over time. The gap exists partly because not every mutation has a matching drug yet, and partly because sequencing results don’t always arrive early enough to shape first-line treatment decisions. Still, for the patients who do get matched, the difference can be significant.
Tracking Outbreaks and Shaping Vaccines
Sequencing is the backbone of how public health agencies monitor infectious diseases. When a new pathogen emerges or an existing virus mutates, sequencing reveals exactly what changed in its genetic code. The CDC, for example, runs a traveler-based genomic surveillance program that sequences samples from arriving international travelers who test positive for select pathogens. This identifies new variants, strains, or mutations before they spread widely within the country.
That genomic data feeds directly into practical decisions: whether a circulating flu strain matches the current vaccine, whether a new COVID variant is likely to evade existing immunity, and whether standard treatments will still work. During the pandemic, sequencing was what allowed scientists to identify variants like Delta and Omicron within weeks of their emergence, giving governments time to adjust public health responses. The same principle applies to tracking antibiotic-resistant bacteria, where sequencing pinpoints exactly which resistance genes a pathogen carries.
Preventing Dangerous Drug Reactions
People metabolize medications differently based on their genetics, and sequencing the handful of genes responsible can prevent serious harm. A large clinical trial called PREPARE found that testing a panel of pharmacogenes before prescribing reduced adverse drug reactions by 30%. Even more striking, an analysis of the United Kingdom’s national pharmacovigilance database found that three-quarters of all genetically preventable adverse reactions were linked to just three genes involved in drug metabolism.
The stakes can be high. Estrogen-based medications, for instance, dramatically increase the risk of life-threatening blood clots in people who carry a specific genetic variant. In the UK database, 86% of blood clot events linked to estrogens in carriers were classified as serious, and 14% were fatal. Similarly, certain antidepressants and antipsychotics can trigger dangerous heart arrhythmias in people with specific genetic profiles. Sequencing these genes before prescribing could have prevented an estimated 34,700 reported adverse reactions captured in that database alone. This type of pre-emptive genetic testing is slowly entering routine care, particularly for drugs with well-documented gene interactions.
Building Hardier Crops
Feeding a growing global population depends partly on developing crop varieties that can resist disease and tolerate changing climates, and sequencing is central to that work. A clear example comes from bread wheat, which supplies roughly 20% of the calories consumed worldwide. Stripe rust, a fungal disease caused by Puccinia striiformis, poses an increasing threat to wheat harvests globally.
Researchers used long-read sequencing to assemble the full 14.7 billion-letter genome of a South African wheat cultivar called Kariega, which shows strong, durable resistance to stripe rust. By mapping this genome at high resolution, they identified the specific resistance gene (Yr27) responsible, an immune receptor that helps the plant fight off the fungus. Pinpointing that gene means breeders can now screen for it in other wheat lines and cross it into vulnerable commercial varieties far more efficiently than traditional breeding alone would allow. The same logic applies to drought tolerance, nutritional content, and resistance to other pathogens across staple crops like rice, maize, and cassava.
Rewriting Human History
Sequencing ancient DNA extracted from bones and teeth has fundamentally changed our understanding of where humans came from and how they moved across the planet. One of the most consequential findings has been confirming that modern humans interbred with Neanderthals and Denisovans, meaning these populations were not the isolated, separate groups scientists once assumed.
Ancient DNA studies published between 2012 and 2018 revealed that the spread of agriculture into Europe wasn’t simply an exchange of ideas between existing populations. It involved a massive physical migration of farming peoples from the Near East, who then mixed with and gradually replaced European hunter-gatherers. Researchers can now trace specific ancestry signatures through time and space. For example, an early Neolithic individual from central Germany shows genetic ties that shift from the Levant around 7500 BC to Anatolia after 7000 BC and then to western Anatolia by 6750 BC, mapping the actual route of population movement following the last ice age. These studies also overturned the assumption that hunter-gatherers were the more mobile populations. In fact, early farmers in Europe moved more frequently and over greater distances.
How Costs Have Changed the Landscape
The original Human Genome Project, completed in 2003, cost between $500 million and $1 billion depending on how you account for the international effort. Generating the initial draft sequence alone ran about $300 million. By mid-2015, a high-quality draft of a full human genome cost just over $4,000, and by late that year it had dropped below $1,500. That cost reduction, faster than Moore’s Law for computer chips, is what made sequencing practical outside of elite research labs.
Today, sequencing is routine in hospital genetics departments, agricultural research stations, public health surveillance labs, and even consumer testing companies. That said, consumer-grade tests and clinical-grade sequencing are not the same thing. Research has shown that direct-to-consumer genetic tests carry a false positive rate of about 40% for pathological gene variants when compared against accredited confirmatory testing. These consumer products are screening tools, not diagnostic ones, and genetic counselors overwhelmingly recommend that any concerning result from a consumer test be confirmed through clinical-grade sequencing before it influences medical decisions.
Why Long-Read Sequencing Expanded What’s Possible
For years, sequencing technology worked by chopping DNA into tiny fragments, reading each one, and computationally stitching the results back together. This short-read approach is fast and cheap but struggles with large structural changes in DNA and repetitive regions of the genome, both of which are common and clinically important. Long-read sequencing reads much larger stretches of DNA in a single pass, eliminating the assembly problem and removing the amplification bias that can distort short-read results.
This matters practically because many genetic diseases are caused by structural variants (large deletions, duplications, or rearrangements) that short-read sequencing simply cannot detect reliably. Long-read methods also reveal epigenetic modifications, chemical tags on DNA that affect how genes are turned on and off without changing the underlying sequence. The ability to capture all of this information in a single, cost-efficient test is why long-read sequencing is increasingly positioned as a first-line diagnostic tool rather than a last resort.